|Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013|
A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ...
Annals of oncology 24 (9), 2206-2223, 2013
|Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer|
C Liedtke, C Mazouni, KR Hess, F André, A Tordai, JA Mejia, ...
Journal of clinical oncology 26 (8), 1275-1281, 2008
|Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy|
L Apetoh, F Ghiringhelli, A Tesniere, M Obeid, C Ortiz, A Criollo, G Mignot, ...
Nature medicine 13 (9), 1050-1059, 2007
|DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy|
KA Olaussen, A Dunant, P Fouret, E Brambilla, F André, V Haddad, ...
New England Journal of Medicine 355 (10), 983-991, 2006
|Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015|
AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ...
Annals of oncology 26 (8), 1533-1546, 2015
|Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors|
F Ghiringhelli, L Apetoh, A Tesniere, L Aymeric, Y Ma, C Ortiz, ...
Nature medicine 15 (10), 1170-1178, 2009
|Palbociclib in hormone-receptor–positive advanced breast cancer|
NC Turner, J Ro, F André, S Loi, S Verma, H Iwata, N Harbeck, S Loibl, ...
New England Journal of Medicine 373 (3), 209-219, 2015
|Ribociclib as first-line therapy for HR-positive, advanced breast cancer|
GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ...
New England Journal of Medicine 375 (18), 1738-1748, 2016
|Malignant effusions and immunogenic tumour-derived exosomes|
F Andre, NEC Schartz, M Movassagh, C Flament, P Pautier, P Morice, ...
The Lancet 360 (9329), 295-305, 2002
|Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial|
B Escudier, T Dorval, N Chaput, F André, MP Caby, S Novault, C Flament, ...
Journal of translational medicine 3 (1), 10, 2005
|ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)|
F Cardoso, A Costa, L Norton, E Senkus, M Aapro, F Andre, CH Barrios, ...
Annals of Oncology 25 (10), 1871-1888, 2014
|Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative …|
C Denkert, G Von Minckwitz, JC Brase, BV Sinn, S Gade, R Kronenwett, ...
J Clin oncol 33 (9), 983-991, 2015
|Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice …|
LN Harris, N Ismaila, LM McShane, F Andre, DE Collyar, ...
Journal of Clinical Oncology 34 (10), 1134, 2016
|De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017|
G Curigliano, HJ Burstein, E P Winer, M Gnant, P Dubsky, S Loibl, ...
Annals of Oncology 28 (8), 1700-1712, 2017
|3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3)|
F Cardoso, A Costa, E Senkus, M Aapro, F André, CH Barrios, J Bergh, ...
Annals of Oncology 28 (1), 16-33, 2017
|The anticancer immune response: indispensable for therapeutic success?|
L Zitvogel, L Apetoh, F Ghiringhelli, F André, A Tesniere, G Kroemer
The Journal of clinical investigation 118 (6), 1991-2001, 2008
|Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy|
A Sistigu, T Yamazaki, E Vacchelli, K Chaba, DP Enot, J Adam, I Vitale, ...
Nature medicine 20 (11), 1301-1309, 2014
|Survival of patients with resected N2 non–small-cell lung cancer: evidence for a subclassification and implications|
F Andre, D Grunenwald, JP Pignon, A Dujon, JL Pujol, PY Brichon, ...
Journal of clinical oncology 18 (16), 2981-2989, 2000
|The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy|
L Apetoh, F Ghiringhelli, A Tesniere, A Criollo, C Ortiz, R Lidereau, ...
Immunological reviews 220 (1), 47-59, 2007
|4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†|
F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ...
Annals of Oncology 29 (8), 1634-1657, 2018